Stagezero Life Sciences (TSE:SZLS) has released an update.
StageZero Life Sciences, a healthcare company specializing in early cancer detection, has been denied a voluntary Management Cease Trade Order by the Ontario Securities Commission due to not meeting the criteria. The company faces potential regulatory action over delayed filing of its annual financial statements and other mandatory reports, which it anticipates completing by May 31, 2024. StageZero is known for its innovative multi-cancer blood test, Aristotle, and provides adjunctive cancer treatments through its COC Protocol.
For further insights into TSE:SZLS stock, check out TipRanks’ Stock Analysis page.
